Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Above average. IRADIMED CORPORATION scores higher than 67% of the 1,794 companies Ryufin scores.
Carried by return on capital and return on new capital, held back by valuation.
Healthcare median 27 · all companies 50
26% of the score, 28% here after data gaps
IRADIMED CORPORATION is valued at 43.5x its operating profit, including debt: past the 25 times where this criterion gives nothing.
18% of the score, 20% here after data gaps
Over 7 years the business earned 52% a year after tax on the capital it uses.
16% of the score, 17% here after data gaps
For every dollar of operating profit earned over 6 years, yearly profit grew by 20 cents. New capital earned 54%, and 36% of profit went back into the business.
14% of the score, 15% here after data gaps
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
12% of the score, 13% here after data gaps
Today's operating margin of 32% is 1.14x its normal 28%: above its usual level. Normal is half the 10 year median, half the last four years, so a margin that has held is not taken for a peak.
Taken out: its 8% is shared by the others
No debt or interest figures on file.
6% of the score, 7% here after data gaps
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For IRMD, balance sheet could not be measured from the filings, so it is taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.